KAI Pharmaceuticals
http://www.kaipharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From KAI Pharmaceuticals
Oncology Reinvents Itself To Retain Position As Biotech Investors’ Darling
Experts from across the biotech ecosystem spoke at a Citeline-sponsored panel at Swiss Biotech Day to discuss how pent-up demand was driving investment in areas outside of oncology, but how there was still room for innovation within the cancer market for those who ask the right questions.
Vividion’s Breakthrough Science Is Fueling Bayer’s Pipeline
Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.
Newron’s Add-On Treatment Shows Promise In Newly Popular Schizophrenia Field
Newron’s evenamide worked in a Phase II/III trial as an add-on to antipsychotic drugs in patients with inadequate response to monotherapy at a time when schizophrenia has piqued the interest of big pharma.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice